Your browser doesn't support javascript.
loading
Cardiac glycosides are broad-spectrum senolytics.
Guerrero, Ana; Herranz, Nicolás; Sun, Bin; Wagner, Verena; Gallage, Suchira; Guiho, Romain; Wolter, Katharina; Pombo, Joaquim; Irvine, Elaine E; Innes, Andrew J; Birch, Jodie; Glegola, Justyna; Manshaei, Saba; Heide, Danijela; Dharmalingam, Gopuraja; Harbig, Jule; Olona, Antoni; Behmoaras, Jacques; Dauch, Daniel; Uren, Anthony G; Zender, Lars; Vernia, Santiago; Martínez-Barbera, Juan Pedro; Heikenwalder, Mathias; Withers, Dominic J; Gil, Jesús.
Afiliación
  • Guerrero A; MRC London Institute of Medical Sciences, London, UK.
  • Herranz N; Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Sun B; MRC London Institute of Medical Sciences, London, UK.
  • Wagner V; Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Gallage S; MRC London Institute of Medical Sciences, London, UK.
  • Guiho R; Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Wolter K; MRC London Institute of Medical Sciences, London, UK.
  • Pombo J; Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Irvine EE; MRC London Institute of Medical Sciences, London, UK.
  • Innes AJ; Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Birch J; Division of Chronic Inflammation and Cancer, German Cancer Research Centre, Heidelberg, Germany.
  • Glegola J; Developmental Biology and Cancer Programme, Birth Defects Research Centre, Great Ormond Street Institute of Child Health, University College London, London, UK.
  • Manshaei S; Department of Internal Medicine VIII, University Hospital Tübingen, Tübingen, Germany.
  • Heide D; Department of Physiology I, Institute of Physiology, Eberhard Karls University Tübingen, Tübingen, Germany.
  • Dharmalingam G; MRC London Institute of Medical Sciences, London, UK.
  • Harbig J; Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Olona A; MRC London Institute of Medical Sciences, London, UK.
  • Behmoaras J; Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Dauch D; MRC London Institute of Medical Sciences, London, UK.
  • Uren AG; Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Zender L; MRC London Institute of Medical Sciences, London, UK.
  • Vernia S; Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Martínez-Barbera JP; MRC London Institute of Medical Sciences, London, UK.
  • Heikenwalder M; Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Withers DJ; Developmental Biology and Cancer Programme, Birth Defects Research Centre, Great Ormond Street Institute of Child Health, University College London, London, UK.
  • Gil J; Division of Chronic Inflammation and Cancer, German Cancer Research Centre, Heidelberg, Germany.
Nat Metab ; 1(11): 1074-1088, 2019 11.
Article en En | MEDLINE | ID: mdl-31799499
ABSTRACT
Senescence is a cellular stress response that results in the stable arrest of old, damaged or preneoplastic cells. Oncogene-induced senescence is tumor suppressive but can also exacerbate tumorigenesis through the secretion of pro-inflammatory factors from senescent cells. Drugs that selectively kill senescent cells, termed senolytics, have proved beneficial in animal models of many age-associated diseases. Here, we show that the cardiac glycoside, ouabain, is a senolytic agent with broad activity. Senescent cells are sensitized to ouabain-induced apoptosis, a process mediated in part by induction of the pro-apoptotic Bcl2-family protein NOXA. We show that cardiac glycosides synergize with anti-cancer drugs to kill tumor cells and eliminate senescent cells that accumulate after irradiation or in old mice. Ouabain also eliminates senescent preneoplastic cells. Our findings suggest that cardiac glycosides may be effective anti-cancer drugs by acting through multiple mechanism. Given the broad range of senescent cells targeted by cardiac glycosides their use against age-related diseases warrants further exploration.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glicósidos Cardíacos / Senescencia Celular Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nat Metab Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glicósidos Cardíacos / Senescencia Celular Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nat Metab Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido
...